Brooks Laboratories Profit & Loss Annual

BSE: 533543 | NSE: BROOKS | ISIN: INE650L01011 | Sector: Major Drugs

143.80 +2.80 (1.99%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	79.49	63.20	91.18	77.25
Total Revenue	79.49	63.20	91.18	77.25
Costof Revenue Total	56.62	57.01	70.62	47.57
Gross Profit	22.87	6.20	20.56	29.67
Selling/ General/ Admin Expenses Total	10.54	28.35	33.11	14.37
Depreciation/ Amortization	1.77	7.03	7.35	7.14
Unusual Expense( Income)	0.00	-0.36	-	-
Other Operating Expenses Total	9.11	4.22	1.49	14.73
Total Operating Expense	78.04	96.25	112.56	83.81
Operating Income	1.44	-33.05	-21.38	-6.57
Interest Inc( Exp) Net- Non- Op Total	-219.66	-51.80	-25.18	-29.37
Other Net	0.96	-0.15	-0.13	0.57
Net Income Before Taxes	-19.57	-38.38	-23.90	-8.99
Provisionfor Income Taxes	0.03	-7.32	-4.59	10.38
Net Income After Taxes	-19.59	-31.05	-19.31	-19.38
Minority Interest	0.00	10.15	8.02	-
Net Income Before Extra Items	-19.59	-20.90	-11.29	-19.38
Net Income	-19.59	-20.90	-11.29	-19.38
Income Availableto Com Excl Extra Ord	-19.59	-20.90	-11.29	-19.38
Income Availableto Com Incl Extra Ord	-19.59	-20.90	-11.29	-19.38
Diluted Net Income	-19.59	-20.90	-11.29	-19.38
Diluted Weighted Average Shares	2.55	2.49	2.49	2.49
Diluted EPS Excluding Extra Ord Items	-7.67	-8.38	-4.53	-7.77
Diluted Normalized EPS	-7.67	-8.47	-4.56	-7.75
Gain( Loss)on Saleof Assets	-	0.00	1.31	-0.56
Total Adjustmentsto Net Income	-	-	0.00	-